|
|
|
| Relationship between GSK-3β and prognosis in patients with glioma |
| ZHAO Kai WANG Zhiwu YANG Junquan |
| The First Department of Chemoradiotherapy, Tangshan People′s Hospital, Hebei Province, Tangshan 063000, China |
|
|
|
Abstract Objective To analyze the relationship between glycogen synthase kinase-3β (GSK-3β) expression and prognosis of glioma patients. Methods Tissue specimens and clinical pathological data of 148 cases who received surgical treatment for glioma in Tangshan People′s Hospital of Hebei Province from January 2010 to December 2014 were collected. According to the expression of GSK-3β, they were devided into GSK-3β high-expression group (85 cases) and GSK-3β low-expression group (63 cases). Age, gender, tumor length and diameter (<4 cm, ≥4 cm), tumor location (frontal lobe, temporal lobe, others), WHO grading data of two groups were collected. Immunohistochemical analysis of GSK-3β expression in tissues, Kaplan-Meier analysis and Cox regression analysis of the relationship between GSK-3β expression and the prognosis of glioma patients. Results GSK-3β expression level was significantly correlated with WHO grade (P < 0.05). The total survival time of GSK-3β high-expression group was shorter than that of GSK-3β low-expression group (HR=2.31, 95%CI: 1.87-4.15, P < 0.01). High GSK-3β expression and WHO grade were the factors affecting poor prognosis. Conclusion The high expression of GSK-3β is related to the poor prognosis of glioma patients, and it is an independent predictor of poor prognosis.
|
|
|
|
|
|
[1] Claes A，Idema AJ，Wesseling P. Diffuse glioma growth：A guerilla war [J]. Acta Neuropathol，2007，114（5）：443-458.
[2] Louis DN，Ohgaki H，Wiestler OD，et al. The 2007 who classification of tumours of the central nervous system [J]. Acta Neuropathol，2007，114（2）：97-109.
[3] Treglia G，Muoio B，Trevisi G，et al. Diagnostic performance and prognostic value of pet/ct with different tracers for brain tumors：A systematic review of published meta-analyses [J]. Int J Mol Sci，2019，20（19）：4669.
[4] Tomiyama A，Ichimura K. Signal transduction pathways and resistance to targeted therapies in glioma [J]. Semin Cancer Biol，2019，58：118-129.
[5] Jaworski T，Banach-Kasper E，Gralec K. Gsk-3beta at the intersection of neuronal plasticity and neurodegeneration [J]. Neural Plast，2019，2019：4209475.
[6] Chen EY，DeRan MT，Ignatius MS，et al. Glycogen synthase kinase 3 inhibitors induce the canonical wnt/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma[J]. Proc Natl Acad Sci U S A，2014，111（14）：5349-5354.
[7] Guo X，Song J，Zhao J，et al. Impact of anxa5 polymorphisms on glioma risk and patient prognosis [J]. J Neurooncol，2019，142（1）：11-26.
[8] Mancinelli R，Carpino G，Petrungaro S，et al. Multifaceted roles of gsk-3 in cancer and autophagy-related diseases [J]. Oxid Med Cell Longev，2017，2017：4629495.
[9] Zhao P，Li Q，Shi Z，et al. Gsk-3beta regulates tumor growth and angiogenesis in human glioma cells [J]. Oncotarget，2015，6（31）：31901-31915.
[10] Chang EF，Clark A，Jensen RL，et al. Multiinstitutional validation of the university of california at san francisco low-grade glioma prognostic scoring system. Clinical article [J]. J Neurosurg，2009，111（2）：203-210.
[11] Molinaro AM，Taylor JW，Wiencke JK，et al. Genetic and molecular epidemiology of adult diffuse glioma [J]. Nat Rev Neurol，2019，15（7）：405-417.
[12] Cheng Q，Cao H，Chen Z，et al. Pax6，a novel target of mir-335，inhibits cell proliferation and invasion in glioma cells [J]. Mol Med Rep，2014，10（1）：399-404.
[13] Walz A，Ugolkov A，Chandra S，et al. Molecular pathways：Revisiting glycogen synthase kinase-3beta as a target for the treatment of cancer [J]. Clin Cancer Res，2017， 23（8）：1891-1897.
[14] Saraswati AP，Ali Hussaini SM，Krishna NH，et al. Glycogen synthase kinase-3 and its inhibitors：Potential target for various therapeutic conditions[J]. Eur J Med Chem，2018，144：843-858.
[15] Wang L，He S，Yuan J，et al. Oncogenic role of sox9 expression in human malignant glioma [J]. Med Oncol，2012，29（5）：3484-3490.
[16] Li B，Li X. Overexpression of hsa_circ_0007534 predicts unfavorable prognosis for osteosarcoma and regulates cell growth and apoptosis by affecting akt/gsk-3beta signaling pathway [J]. Biomed Pharmacother，2018，107：860-866.
[17] Miyashita K，Kawakami K，Nakada M，et al. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma [J]. Clin Cancer Res，2009，15（3）：887-897.
[18] Yang Y，Lei T，Du S，et al. Nuclear gsk 3beta induces DNA double-strand break repair by phosphorylating 53bp1 in glioblastoma [J]. Int J Oncol，2018，52（3）：709-720.
[19] Zhou A，Lin K，Zhang S，et al. Nuclear gsk 3beta promotes tumorigenesis by phosphorylating kdm1a and inducing its deubiquitylation by USP22 [J]. Nat Cell Biol，2016，18（9）：954-966.
[20] Kitabayashi T，Dong Y，Furuta T，et al. Identification of gsk3beta inhibitor kenpaullone as a temozolomide enhancer against glioblastoma[J]. Sci Rep，2019，9（1）：10049. |
|
|
|
